David S. Miller

Gynecologic Oncology Group — United States

Medicine · Health Sciences

101h-index42.9kcitations1.0kworks3.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Endometrial and Cervical Cancer Treatments(189), Ovarian cancer diagnosis and treatment(168), Drug Transport and Resistance Mechanisms(117), Cervical Cancer and HPV Research(52), Computational Fluid Dynamics and Aerodynamics(51)

Publications1.0k total

Phase II Trial of Ribociclib Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube, or Peritoneum: A GOG Partners Trial (GOG 3026)
Journal of Clinical Oncology·2025· 2 cited
Impact of Interruptions in Chemotherapy on Survival for Patients With Metastatic or Recurrent Cervical Cancer
American Journal of Clinical Oncology·2025
Anger-related affect and suicidal thoughts and behaviors: A systematic review and meta-analysis.
Clinical Psychology Science and Practice·2025· 1 citedOpen Access
LONG-TERM FOLLOW-UP OF SELINEXOR MAINTENANCE TREATMENT IN PATIENTS WITH TP53 WILD TYPE ADVANCED/RECURRENT ENDOMETRIAL CANCER: INTERMEDIATE ENDPOINTS BY MISMATCH REPAIR STATUS IN THE ENGOT-EN5/GOG-3055/SIENDO STUDY
International Journal of Gynecological Cancer·2025
POST-(NEO)ADJUVANT THERAPY OUTCOMES WITH LENVATINIB PLUS PEMBROLIZUMAB IN PARTICIPANTS WITH ADVANCED OR RECURRENT ENDOMETRIAL CANCER: RESULTS FROM STUDY 309/KEYNOTE-775 AND ENGOT-EN9/LEAP-001
International Journal of Gynecological Cancer·2025
Abstract B012: Results From the Phase 1 Dose Escalation and Dose Expansion Study of Azenosertib, a WEE1 Inhibitor, in Patients With Advanced Solid Tumors
Molecular Cancer Therapeutics·2025
Prospective assessment of prognostic significance of malignant peritoneal cytology in endometrial cancer: An NRG Oncology / Gynecologic Oncology Group study on GOG-210 protocol
Gynecologic Oncology·2025Open Access
1119P Lenvatinib plus pembrolizumab (L + P) vs treatment of physician’s choice (TPC) for advanced endometrial cancer (EC): 5-year outcomes from study 309/KEYNOTE-775
Annals of Oncology·2025
High concordance between immunohistochemistry and next generation sequencing for determining TP53 mutation status in endometrial cancer: A post hoc analysis of the ENGOT-EN5/GOG-3055/SIENDO study
Gynecologic Oncology·2025
1153P Clinical and biomarker results from E7386 study 102: Global dose-expansion cohort of E7386 + lenvatinib (LEN) in patients (pts) with advanced/recurrent endometrial cancer (aEC) that progressed on platinum-based chemotherapy (PBC) and an anti-PD-(L)1 immunotherapy (IO)
Annals of Oncology·2025
Supplementary Table S1 from Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial
2025Open Access
Supplementary Figure S2 from Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial
2025Open Access
Supplementary Table S2 from Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial
2025Open Access
Data from Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial
2025Open Access
Supplementary Figure S1 from Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial
2025Open Access
Supplementary Table S3 from Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial
2025Open Access
Supplementary Appendix S1 from Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial
2025Open Access
68O Blood ctDNA vs tumor tissue screening for the detection of KRAS mutations in low-grade serous ovarian cancer
ESMO Open·2025· 1 citedOpen Access
Correlation of survival to length of neoadjuvant chemotherapy in high-grade epithelial ovarian cancer
Gynecologic Oncology Reports·2025Open Access
44P Long-term follow-up of selinexor (SEL) maintenance treatment in patients with TP53 wild type (wt) advanced/recurrent (A/R) endometrial cancer (EC): Intermediate endpoints by mismatch repair (MMR) status in the ENGOT-EN5/GOG-3055/SIENDO study
ESMO Open·2025Open Access
page 1 of 50Next →

Frequent Co-authors

Björn Bauer(9), Anika M. S. Hartz(6), Constantine G. Lyketsos(5), Paul DiSilvestro(5), Virginia L. Filiaci(5), Sean M. Grimmond(4), Daniela Matei(4), Gert Fricker(4), Robert S. Mannel(4), Nicola Waddell(3), Ann‐Marie Patch(3), Peter J. Bailey(3), Kátia Nones(3), Angelika N. Christ(3), Suzanne Manning(3), Craig Nourse(3), J. Lynn Fink(3), Stephen H. Kazakoff(3), Conrad Leonard(3), John V. Pearson(3)